The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.

TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...

Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.